Dr Wilson, has over 19 years of experience in cancer research projects focused on identifying mechanisms to improve the effectiveness of chemotherapeutic agents in human cancers. Since 2014, he has held the position of Scientific Director of Drug Development at CV6 Therapeutics (NI) Ltd.

Dr Wilson’s research has focused on cellular signaling pathways and the mechanisms that regulate chemotherapeutic drug resistance to commonly used cancer chemotherapeutics that target nucleotide biosynthesis. He has identified and characterized novel drug targets in the nucleotide biosynthetic pathway that mediate clinical resistance to DNA damaging chemotherapeutics and developed a novel drug-screening platform to identify candidate inhibitors as a focused preclinical drug development strategy. Dr Wilson has extensive experience in translational cancer medicine having been a key member of a translational research initiative at the University of Southern California (USC) Norris Comprehensive Cancer Center where he completed his postdoctoral training. During this project, he was responsible for managing the preclinical research that led directly to the initiation of two Phase I biomarker-embedded clinical trials in advanced colorectal cancer at USC.

He was awarded a BSc (Hons) in genetics from the Queen’s University Belfast in 2000 where he remained on to complete his PhD in molecular onocology under the supervision of Prof. Patrick G. Johnston having been awarded a Northern Ireland Health and Personal Social Services Research and Development Studentship.